Authors
Latest:
Evolving Landscape of HR+ Metastatic Breast Cancer ManagementClosing out their review of treatment strategies for HR+ metastatic breast cancer, a panel of experts highlights ongoing investigations and future directions in care.
Latest:
Future Directions in Advanced RCCPanelists discuss future directions in the treatment of advanced renal cell carcinoma (RCC), focusing on emerging therapies, clinical trials, and potential advancements in patient disease management.
Latest:
Squamous Cell Carcinoma of the Kidney: A Large Case SeriesSyed Arslan Shehzad Shah, MD, and colleagues present findings from a broad investigation into this rare neoplasm of the kidney, including data on patient demographics and mean survival.
Latest:
Key CAR T and Transplantation Presentations From The 2025 Tandem MeetingShernan Holtan, MD, and Rahul Banerjee, MD, FACP, discussed various trials of significance shared as posters and presentations at the 2025 Tandem Meeting.
Latest:
Molecular Profiling in Metastatic Colorectal CancerABSTRACT: Colorectal cancer (CRC) is a commonly diagnosed malignancy. Although chemotherapy remains the backbone of treatment, the landscape of treating metastatic CRC (mCRC) is changing with the understanding of its heterogeneity and molecular blueprint. Colon cancer sidedness has proven to hold prognostic implications, with right-sided tumors having higher incidence of BRAF and KRAS mutations and being microsatellite instability–high (MSI-H); overall, they have a worse prognosis compared with left sided-tumors. Results of molecular research have demonstrated the need to profile each mCRC patient for RAS and BRAF mutations, MSI-H status, HER2 amplifications, and NTRK fusions. Ongoing clinical trials using targeted agents aim to further improve survival outcomes. We emphasize the epidemiology, knowledge of primary tumor location, and mutational landscape of mCRC, as well as novel treatment options for patients harboring unique subtypes of these characteristics.
Latest:
Collaborative Care and Access Challenges in Managing R/R MM with GPRC5D BispecificOncology Clinical Pharmacist Specialist Amir Ali delves into potential challenges related to access and the use of this therapy, providing a comprehensive perspective on the complexities of incorporating GPRC5-targeting bispecifics into R/R MM patient management.
Latest:
Perioperative Telemonitoring Yields “Encouraging” Results in GI CancersPatient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Latest:
Oncology Peer Review On-The-Go Podcast: Cervical Cancer Screenings/Survival in Those 65+ YearsJulianne Cooley, MS, spoke with CancerNetwork® about older patients with later stage cervical cancer who have lower survival rates compared with their younger counterparts.
Latest:
Life Experience of Survivors of Gynecologic Cancers: A Survey Conducted in ItalyA survey was conducted in Italy for survivors of gynecologic cancer regarding quality of life, specifically that of sexual activity after a cancer diagnosis.
Latest:
Addressing Social Norms Influencing Receipt of Aggressive End-of-Life CareAccording to Megan Mullins, PhD, MPH, challenging cultural norms surrounding death and dying may reduce the receipt of low-value end-of-life cancer care.
Latest:
Future Perspectives in the Treatment and Management of Patients With EGFR-Mutated NSCLCMisako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C, emphasize the importance of patient education, discussing how understanding the biological reasons behind treatments for EGFR-mutated non-small cell lung cancer and their side effects can lead to better outcomes, and highlighting the need for collaborative care and clear communication.
Latest:
Treatment Considerations for Bispecific Antibodies and Unmet Needs in MMThe expert panel overviews factors to consider with bispecific antibodies and offers closing insights on unmet needs in the multiple myeloma treatment space.
Latest:
Future of R/R MM: Emerging AgentsIn this segment, Dr Mohan asks Dr Mann about emerging investigational agents for the management of relapsed/refractory multiple myeloma (R/R MM) that show particular promise.
Latest:
Patient-Centered Approaches in EGFR-Mutated NSCLCPanelists discuss how oral and subcutaneous therapies have improved the quality of life for patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC), with Squires sharing patient benefits from newer administration routes, and Dr Scott highlighting promising developments in EGFR-mutated NSCLC treatments, while exploring the evolving role of patient empowerment, self-management, and the multidisciplinary care team in supporting patients through home-based care and active participation in their treatment journey.
Latest:
EC Approves T-DXd Monotherapy in HR+, HER2-Low/Ultralow Breast CancerResults from the phase 3 DESTINY-Breast06 trial demonstrated that T-DXd monotherapy improved PFS over chemotherapy in patients with breast cancer.
Latest:
Exploring New Possibilities in Kidney Cancer Detection and TherapyExperts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.
Latest:
Constantine Si Lun Tam, MD, MBBS, FRACP, FRCPA, on Key Highlights of the Phase 3 ASPEN TrialThe trial evaluated zanubrutinib, a potent and selective BTK inhibitor, versus ibrutinib, a first generation BTK inhibitor, in patients with Waldenström macroglobulinemia.
